Huntington’s Disease
Huntington disease (HD) Verified · Sep 2026NINDS: "Huntington's disease (HD) is an inherited disorder that causes nerve cells (neurons) in parts of the brain to slowly break down and die. The disease affects areas of the brain that control voluntary (intentional) movement." StatPearls: it "is characterized by the clinical triad of involuntary choreiform movements with cognitive and behavioral disturbances."
HD is autosomal dominant: one altered copy of the gene is enough, and "The chance that each offspring of a patient with Huntington disease will develop the disease is 50%." Mood and thinking often change before the movements do. The nurse watches three things closely: swallowing (choking, aspiration, weight loss), falls and injury, and suicide risk — especially when a VMAT2 inhibitor is started. Suicidal thoughts in a patient with HD are evaluated immediately.
What’s going wrong in the body
The normal physiology, where it fails, and why the body’s compensation backfires.
01 An autosomal dominant repeat expansion
"HD is caused by a change in the gene that makes the protein huntingtin (HTT). This change causes a section of DNA called CAG to repeat itself many more times than normal, causing production of an abnormal version of huntingtin that damages brain cells" (NINDS). The gene sits on chromosome 4.
Inheritance. "When a parent has HD, each child has a 50% chance of inheriting the genetic variant. If a child does not inherit the variant, they won’t develop the disease and can’t pass it on to future generations" (NINDS). MedlinePlus Genetics: one copy of the altered gene in each cell "is sufficient to cause the disorder."
Repeat length matters (figures differ slightly by source). NINDS: "Most people have fewer than 27 CAG repeats in their HD gene, so they aren’t at risk for the disease." "People who have CAG repeats in the middle range (27 to 35) aren’t likely to develop the disease, but they could still pass it on to future generations." "People with HD may have 36 or more CAG repeats." MedlinePlus Genetics: "People with 36 to 39 CAG repeats may or may not develop the signs and symptoms of Huntington's disease, while people with 40 or more repeats almost always develop the disorder."
Anticipation. As the gene passes down a family, the repeat often grows, and "A larger number of repeats is usually associated with an earlier onset of signs and symptoms" (MedlinePlus Genetics). StatPearls: "In Huntington disease, the anticipation phenomenon is seen mainly in the paternal line of inheritance, which arises due to the instability of the CAG repeats during spermatogenesis." A negative family history does not rule HD out — the parent may have died early, had late-onset disease or never been diagnosed.
02 Toxic huntingtin and the striatum
"An increase in the size of the CAG segment leads to the production of an abnormally long version of the huntingtin protein. The elongated protein is cut into smaller, toxic fragments that bind together and accumulate in neurons, disrupting the normal functions of these cells" (MedlinePlus Genetics).
The striatum fails first. "The primary feature is the degeneration of neurons of the striatum, ie, the putamen and the caudate." Most striatal projection neurons are GABAergic, and "Throughout Huntington disease, over 90% of these GABAergic neurons degenerate" (StatPearls). The typical MRI finding is caudate atrophy with a "boxcar appearance" (StatPearls, Chorea).
Why the movements happen. "Striatal modulation is mainly inhibitory through GABAergic innervation. Consequently, any striatal lesion can disrupt this inhibitory mechanism, resulting in hyperkinetic movement disorders such as chorea or choreoathetosis." These disorders "are believed to result from increased phasic dopaminergic signaling in the striatum" (StatPearls, Chorea). That is why drugs that deplete dopamine (VMAT2 inhibitors) reduce chorea.
Beyond movement. Neurodegeneration also occurs "throughout the cerebral cortex," and "The involvement of the cingulate gyrus is associated with emotion and mood disturbances" (StatPearls). Brain changes start early: "measurable brain and behavioral changes can be detected up to 15 years before an HD diagnosis" (NINDS).
03 The triad over time — and what ends life
"The signs and symptoms classically consist of the triad of motor, cognitive, and psychiatric disturbances" (StatPearls). Motor signs are not always first: "Behavioral and psychiatric symptoms are present very early in the disease, often even before the onset of motor manifestations" (StatPearls), and motor symptoms "are frequently preceded by cognitive and behavioral symptoms" (EHDN guideline).
Onset and course (attributed). "Huntington disease commonly affects patients between the ages of 30 to 50" (StatPearls); NHS says symptoms "usually start in adults aged between 30 and 50, but it can happen at any age." Adults "usually live about 15 to 20 years after signs and symptoms begin" (MedlinePlus Genetics). Early chorea is hyperkinetic; "In later stages, however, hypokinesia with bradykinesia and dystonia may predominate" (StatPearls). Juvenile HD (onset before age 20, StatPearls) is rare (NINDS).
Swallowing, weight and the lungs. "Dysarthria and dysphagia develop during the course of the disease, which could lead to aspiration in patients, with pneumonia being a common cause of death" (StatPearls). The EHDN guideline adds that swallowing disorders can become "a major problem in later stages by inducing repeated choking and leading to secondary bronchopulmonary infections or even cardiac arrest." Weight loss "might occur despite normal, or even high calorie intake, due to a significant energy expenditure in HD patients" (EHDN).
Causes of death. "Aspiration pneumonia is the most frequent cause of death, which is followed by suicide" (StatPearls). "Approximately 25% of the patients attempt suicide" (StatPearls).
Causes & risk factors
Modifiable factors are teaching targets — the patient can act on them.
Signs & symptoms
Each finding tied to the mechanism that produces it — and the triage it calls for.
Diagnostics
Complications
Medications for this condition
Why each class is prescribed here — every card links to its full pharmacology page.
Chorea with behavioral or psychotic symptoms; aggression (off-label). NINDS: "Antipsychotic medicines, such as risperidone and olanzapine, may help calm chorea movements and also treat psychiatric symptoms," but "Some antipsychotic medicines can make movement-related symptoms worse in people with HD." EHDN (2019): second-generation neuroleptics (Grade B) are first-line for chorea "in particular when the patients have associated personality and/or behavioral or psychotic disorders," and a neuroleptic is the first-line treatment for aggressive behavior (Grade C); monotherapy is preferred. StatPearls: evidence "is inconsistent," with extrapyramidal effects "including akathisia and tardive dyskinesia." Do not combine QTc-prolonging antipsychotics with tetrabenazine (XENAZINE label).
Depression and irritability. EHDN (2019): "It is recommended to use a selective SSRI or a serotonin noradrenaline reuptake inhibitor (SNRI)" for depression, and "SSRIs are first lines for irritability (Grade C)." StatPearls cautions that "no convincing evidence of their use in Huntington disease has been documented." Fluoxetine and paroxetine are strong CYP2D6 inhibitors that limit the tetrabenazine dose (XENAZINE label).
Beyond medications
- VMAT2 inhibitors for chorea (no class page — prose only). Tetrabenazine, deutetrabenazine and valbenazine "decrease dopamine's bioavailability in the synapses" (StatPearls). EHDN (2019): "Tetrabenazine is one of the first-line treatments for this symptom (Grade A)" — "unless the patient suffers from not well-managed depression or suicidal thoughts." AUSTEDO tablets are swallowed whole — not chewed, crushed or broken; INGREZZA SPRINKLE capsules may be opened over soft food. Tetrabenazine above a set daily dose requires CYP2D6 genotyping (XENAZINE label). No doses here.
- No cure, no approved disease-modifying drug. "There is no treatment that can stop or reverse HD, but some of the symptoms can be treated" (NINDS). "No pharmacological agent is effective or indicated for cognitive impairment in Huntington disease" (StatPearls).
- Team care (NHS): antidepressants and talking therapies such as CBT, medicines for chorea, "physiotherapy to help with movement problems," "occupational therapy to help with daily activities," and "speech and language therapy." NINDS adds mental health professionals and genetic counselors.
- Nutrition (EHDN, Grade C). "Good nutritional care is a fundamental element of the management of HD." "A high Body Mass Index (BMI) within normal values should be maintained if possible," and when weight is lost, "high-calorie and high-protein food supplements should be prescribed under instruction and monitored by a dietician/nutritionist."
- Swallowing (EHDN). "Provision of information and advice on safe swallowing procedures, on posture and positional changes can help to avoid aspirations." A PEG "should be anticipated and discussed with relatives and patients still able to understand the benefits and burdens of the methods."
- Falls prevention (EHDN). Physiotherapy (Grade B), falls-prevention, gait and balance programs (Grade C), and a four-wheeled walker (Grade B) "to improve stability and reduce fall risk." "Maintaining physical activity and low impact exercises is recommended."
- Irritability (EHDN). "Before initiating pharmacological treatment, possible environmental causes for the patient's frustration and irritability should be explored." "A structured plan with a regular routine in a calming environment is desirable."
- Supportive care (StatPearls): attention to diet, nursing and special equipment; "smoking and alcohol use is discouraged"; emotional support and counseling for patients and families.
Nursing considerations
The RN-specific layer — each action paired with the reason it matters.
How a real nurse thinks
The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.
- 1 Recognize cues
A possible statement of hopelessness on a VMAT2 inhibitor, coughing at meals, weight loss despite eating, and falls with a head bruise.
- 2 Analyze cues
Tetrabenazine carries a boxed warning for depression and suicidality in HD, and "Patients with HD who express suicidal ideation should be evaluated immediately." Coughing at meals points to dysphagia and aspiration risk; aspiration pneumonia is the most frequent cause of death. Weight loss can occur "despite normal, or even high calorie intake." Chorea can cause "fractures and head trauma."
- 3 Prioritize
Safety from suicide first (an immediate evaluation), then airway and aspiration at meals, then nutrition and falls.
- 4 Generate solutions
Ask him directly about suicidal thoughts, keep him under observation, and notify the provider now for an immediate evaluation; hold the next tetrabenazine dose pending review. Stop the meal, sit him upright and request a swallowing assessment. Ask the dietitian about high-calorie, high-protein supplements. Put fall precautions in place and report the head bruise.
- 5 Take action
Stays with him, asks about suicidal thoughts, and calls the provider for an immediate evaluation; documents the sister’s report; stops the meal and positions him upright; places a speech-therapy referral and dietitian consult; starts fall precautions.
- 6 Evaluate
Confirms the suicide evaluation happened and the safety plan is in place; watches the next meals for coughing; tracks weekly weight; counts falls.
Scenario — you’re the nurse
Work each question before revealing the answer. Rationales explain the wrong options too.
A 48-year-old man with Huntington’s disease diagnosed 6 years ago. His father had HD. He takes tetrabenazine for chorea. His sister visits daily.
Q1 Multiple choice The sister of a patient with Huntington’s disease asks what the chance is that her own child could inherit the gene from her if she has it. What should the nurse say? - A. 25%, because HD is autosomal recessive
- B. 50% for each child, because HD is autosomal dominant
- C. Only sons can inherit it
- D. There is no risk unless both parents have HD
Reveal answer & rationale
Q2 Multiple choice A patient with HD taking tetrabenazine tells the nurse, ‘My family would be better off without me.’ What is the priority action? - A. Document the statement and recheck at the next shift
- B. Ask about suicidal thoughts and arrange an immediate evaluation
- C. Give the next tetrabenazine dose to calm him
- D. Encourage him to join an HD support group
Reveal answer & rationale
Q3 Select all that apply Which findings in a patient with HD should the nurse report to the provider? Select all that apply. - A. Coughing during meals
- B. Unintended weight loss over 3 months
- C. Two falls this week
- D. New withdrawal and insomnia after starting tetrabenazine
- E. Mild chorea that does not bother the patient
Reveal answer & rationale
Q4 Multiple choice A patient with HD is losing weight despite eating full meals. Which dietary approach is appropriate? - A. Restrict calories to slow weight change
- B. High-calorie, high-protein supplements under a dietitian
- C. A low-protein diet to reduce movement
- D. Clear liquids only
Reveal answer & rationale
Q5 Multiple choice A patient taking AUSTEDO has worsening dysphagia. The caregiver asks whether she can crush the tablet into applesauce. What should the nurse say? - A. Yes, crushing is fine with food
- B. No — AUSTEDO is swallowed whole; ask the prescriber about the swallowing problem
- C. Yes, but only with milk
- D. Skip the dose on days swallowing is hard
Reveal answer & rationale
Common questions
What causes huntington’s disease?
If I have the gene, will I definitely get Huntington’s disease?
Can HD skip a generation or appear with no family history?
Why do chorea medicines need so much monitoring?
Is there a cure?
What usually causes death in HD?
Sources
- Huntington Disease — StatPearls — StatPearls (NCBI Bookshelf)
- Huntington’s Disease (last reviewed July 23, 2026) — National Institute of Neurological Disorders and Stroke (NIH)
- Huntington’s disease — MedlinePlus Genetics — National Library of Medicine (NIH)
- International Guidelines for the Treatment of Huntington’s Disease (Bachoud-Lévi et al., Front Neurol 2019; CC BY) — Frontiers in Neurology (PubMed Central)
- XENAZINE (tetrabenazine) — FDA label (DailyMed) — U.S. Food and Drug Administration / DailyMed
- AUSTEDO XR / AUSTEDO (deutetrabenazine) — FDA label (DailyMed) — U.S. Food and Drug Administration / DailyMed
- INGREZZA / INGREZZA SPRINKLE (valbenazine) — FDA label (DailyMed) — U.S. Food and Drug Administration / DailyMed
- Huntington’s disease — NHS. Contains public sector information licensed under the Open Government Licence v3.0 (https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/) — NHS
- Chorea — StatPearls — StatPearls (NCBI Bookshelf)
Reviewed by Hae Suk Lee, RN
Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.